English English Spanish Spanish
Latest Physician News2019-02-15T12:10:02+00:00

Latest in Sleep Medicine News

Obstructive sleep apnea: focus on myofunctional therapy


Orofacial myofunctional therapy (OMT) is a modality of treatment for children and adults with obstructive sleep apnea (OSA) to promote changes in the musculature of the upper airways. This review summarizes and discusses the effects of OMT on OSA, the therapeutic programs employed, and their possible mechanisms of action.


We conducted an online literature search using the databases MEDLINE/PubMed, EMBASE, and Web of Science. Search terms were “obstructive sleep apnea” in combination with “myofunctional therapy” OR “oropharyngeal exercises” OR “speech therapy”. We considered original articles in English and Portuguese containing a diagnosis of OSA based on polysomnography (PSG). The primary outcomes of interest for this review were objective measurement derived from PSG and subjective sleep symptoms. The secondary outcome was the evaluation of orofacial myofunctional status.


Eleven studies were included in this review. The studies reviewed reveal that several benefits of OMT were demonstrated in adults, which include significant decrease of apnea-hypopnea index (AHI), reduced arousal index, improvement in subjective symptoms of daytime sleepiness, sleep quality, and life quality. In children with residual apnea, OMT promoted a decrease of AHI, increase in oxygen saturation, and improvement of orofacial myofunctional status. Few of the studies reviewed reported the effects of OMT on the musculature.


The present review showed that OMT is effective for the treatment of adults in reducing the severity of OSA and snoring, and improving the quality of life. OMT is also successful for the treatment of children with residual apnea. In addition, OMT favors the adherence to continuous positive airway pressure. However, randomized and high-quality studies are still rare, and the effects of treatment should also be analyzed on a long-term basis, including measures showing if changes occurred in the musculature.

Source: https://www.ncbi.nlm.nih.gov/pubmed/30233265

Obstructive sleep apnea: Who should be tested, and how?

Patients who have risk factors for obstructive sleep apnea (OSA) or who report symptoms of OSA should be screened for it, first with a complete sleep history and standardized questionnaire, and then by objective testing if indicated. The gold standard test for OSA is polysomnography performed overnight in a sleep laboratory. Home testing is an option in certain instances.

Common risk factors include obesity, resistant hypertension, retrognathia, large neck circumference (> 17 inches in men, > 16 inches in women), and history of stroke, atrial fibrillation, nocturnal arrhythmias, heart failure, and pulmonary hypertension. Screening is also recommended for any patient who is found on physical examination to have upper-airway narrowing or who reports symptoms such as loud snoring, observed episodes of apnea, gasping or choking at night, unrefreshing sleep, morning headaches, unexplained fatigue, and excessive tiredness during the day.

The American Academy of Sleep Medicine suggests three opportunities to screen for OSA1:

  • At routine health maintenance visits
  • If the patient reports clinical symptoms of OSA
  • If the patient has risk factors.


The prevalence of OSA in the United States is high, estimated to be 2% in women and 4% in men in the middle-aged work force,2 and even more in blacks, Asians, and older adults.3 Yet only 10% of people with OSA are diagnosed4—a dismal statistic considering the association of OSA with resistant hypertension5 and with a greater risk of stroke,6cardiovascular disease, and death.7


Untreated OSA is associated with a number of conditions7:

  • Hypertension. OSA is one of the most common conditions associated with resistant hypertension. Patients with severe OSA and resistant hypertension who comply with continuous positive airway pressure (CPAP) treatment have significant reductions in blood pressure.
  • Coronary artery disease. OSA is twice as common in people with coronary artery disease as in those with no coronary artery disease. In patients with coronary artery disease and OSA, CPAP may reduce the rate of nonfatal and fatal cardiovascular events.
  • Heart failure. OSA is common in patients with systolic dysfunction (11% to 37%). OSA also has been detected in more than 50% of patients with heart failure with preserved systolic function. CPAP treatment can improve ejection fraction in patients with systolic dysfunction.
  • Arrythmias. Atrial fibrillation, nonsustained ventricular tachycardia, and complex ventricular ectopy have been reported to be significantly more common in people with OSA.8 If the underlying cardiac conduction system is normal and there is no significant thyroid dysfunction, bradyarrhythmias and heart block may be treated effectively with CPAP.7 Treatment of OSA may decrease the incidence and severity of ventricular arrhythmias.7
  • Sudden cardiac death. OSA was independently associated with sudden cardiac death in a longitudinal study.9
  • Stroke. The Sleep Heart Health Study6 showed that OSA is 30% more common in patients who developed ischemic stroke. Long-term CPAP treatment in moderate to severe OSA and ischemic stroke is associated with a reduction in the mortality rate.10
  • Diabetes. The Sleep Heart Health Study showed that OSA is independently associated with glucose intolerance and insulin resistance and may lead to type 2 diabetes mellitus.11


If you suspect OSA, consider administering a sleep disorder questionnaire such as the Berlin,12 the Epworth Sleepiness Scale, or the STOP-Bang questionnaire (Table 1). The STOP-Bang questionnaire is an easy-to-use tool that expands on the STOP questionnaire (snoring, tiredness, observed apnea, high blood pressure) with the addition of body mass index, age, neck size, and gender. The Berlin questionnaire has been validated in the primary care setting.12 The STOP-Bang questionnaire has been validated in preoperative settings13 but not in the primary care setting (although it has been commonly used in primary care).


If the score on the questionnaire indicates a moderate or high risk of OSA, the patient should undergo objective testing with polysomnography or, in certain instances, home testing.1Polysomnography is the gold standard. Home testing costs less and is easier to arrange, but the American Academy of Sleep Medicine recommends it as an alternative to polysomnography, in conjunction with a comprehensive sleep evaluation, only in the following situations14:

  • If the patient has a high pretest probability of moderate to severe OSA
  • If immobility or critical illness makes polysomnography unfeasible
  • If direct monitoring of the response to non-CPAP treatments for sleep apnea is needed.

Home testing for OSA should not be used in the following situations:

  • If the patient has significant morbidity such as moderate to severe pulmonary disease, neuromuscular disease, or congestive heart failure
  • In evaluating a patient suspected of having comorbid sleep disorders such as central sleep apnea, periodic limb movement disorder, insomnia, parasomnias, circadian rhythm disorder, or narcolepsy
  • In screening of asymptomatic patients.

Home testing has important drawbacks. It may underestimate the severity of sleep apnea. The rate of false-negative results may be as high as 17%. If the home test was thought to be technically inadequate or the results were inconsistent with those that were expected—ie, if the patient has a high pretest probability of OSA based on risk factors or symptoms but negative results on home testing—then the patient should undergo polysomnography.14


The diagnosis of OSA is confirmed if the number of apnea events per hour (ie, the apnea-hypopnea index) on polysomnography or home testing is more than 15, regardless of symptoms, or more than 5 in a patient who reports OSA symptoms. An apnea-hypopnea index of 5 to 14 indicates mild OSA, 15 to 30 indicates moderate OSA, and greater than 30 indicates severe OSA.


Treatment of OSA with CPAP reduces the 10-year risk of fatal and nonfatal motor vehicle accidents by 52%, the 10-year expected number of myocardial infarctions by 49%, and the 10-year risk of stroke by 31%.7 It has also been found to be cost-effective, for men and women of all ages with moderate to severe OSA.15

Insomnia in the Elderly: A Review

Insomnia remains one of the most common complaints among elderly patients. However, treatment options are not easily understood among primary care physicians. There are risks of overuse of sedatives without proper analysis of underlying risk factors for insomnia. Cognitive behavioral therapy remains a viable treatment option in addition to pharmacological therapy. This review article outlines evidence-based treatment options for insomnia.

Source:Patel D, Steinberg J, Patel P. Insomnia in the elderly: a review. J Clin Sleep Med. 2018;14(6):1017–1024.

Latest in Sleep Medicine Research

  1. Mulholland, GB, Jeffery, CC, Ziai, H, Hans, V, Seikaly, H, Pang, KP et al.. Multilevel Palate and Tongue Base Surgical Treatment of Obstructive Sleep Apnea: A Systematic Review and Meta-analysis. Laryngoscope. 2019; :. doi: 10.1002/lary.27597. PubMed PMID:30908658 .
  2. Wegner, I, Hall, DA, Smit, AL, McFerran, D, Stegeman, I. Betahistine for tinnitus. Cochrane Database Syst Rev. 2018;12 :CD013093. doi: 10.1002/14651858.CD013093.pub2. PubMed PMID:30908589 .
  3. Bolash, R, Creamer, M, Rauck, R, Vahedifar, P, Calodney, A, Fox, I et al.. Wireless High-Frequency Spinal Cord Stimulation (10 kHz) Compared with Multiwaveform Low-Frequency Spinal Cord Stimulation in the Management of Chronic Pain in Failed Back Surgery Syndrome Subjects: Preliminary Results of a Multicenter, Prospective Randomized Controlled Study. Pain Med. 2019; :. doi: 10.1093/pm/pnz019. PubMed PMID:30908577 .
  4. Hamanishi, S, Eguchi, E, Ito, T, Nagaoka, K, Ogino, K. Head cooling during sleep improves sleep quality in the luteal phase in female university students: A randomized crossover-controlled pilot study. PLoS ONE. 2019;14 (3):e0213706. doi: 10.1371/journal.pone.0213706. PubMed PMID:30908497 .
  5. Wu, SH, Chu, CJ, Lin, CC, Su, CW, Lee, SD, Wang, YJ et al.. A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin. J Chin Med Assoc. 2019;82 (3):186-190. doi: 10.1097/JCMA.0000000000000069. PubMed PMID:30908411 .
  6. Kwon, SJ, Kim, Y, Kwak, Y. Relationship of sleep quality and attention deficit hyperactivity disorder symptoms with quality of life in college students. J Am Coll Health. 2019; :1-7. doi: 10.1080/07448481.2019.1583650. PubMed PMID:30908170 .
  7. Cahuas, A, He, Z, Zhang, Z, Chen, W. Relationship of physical activity and sleep with depression in college students. J Am Coll Health. 2019; :1-8. doi: 10.1080/07448481.2019.1583653. PubMed PMID:30908132 .
  8. Van der Touw, T, Andronicos, NM, Smart, N. Is C-reactive protein elevated in obstructive sleep apnoea? A systematic review and meta-analysis. Biomarkers. 2019; :1-21. doi: 10.1080/1354750X.2019.1600025. PubMed PMID:30908094 .
  9. Hallit, S, Hajj, A, Sacre, H, Al Karaki, G, Malaeb, D, Kheir, N et al.. Impact of Sleep Disorders and Other Factors on the Quality of Life in General Population: A Cross-Sectional Study. J. Nerv. Ment. Dis. 2019; :. doi: 10.1097/NMD.0000000000000968. PubMed PMID:30907768 .
  10. Wong, MM, Craun, EA, Bravo, AJ, Pearson, MR, Protective Strategies Study Team. Insomnia symptoms, cannabis protective behavioral strategies, and hazardous cannabis use among U.S. college students. Exp Clin Psychopharmacol. 2019; :. doi: 10.1037/pha0000273. PubMed PMID:30907602 .
  11. Lupi-Ferandin, S, Galic, T, Ivkovic, N, Pecotic, R, Dogas, `. Prevalence of obstructive sleep apnea in male patients with surgically treated maxillary and zygomatic fractures. Can J Surg. 2019;62 (2):105-110. doi: 10.1503/cjs.002818. PubMed PMID:30907566 .
  12. Wassing, R, Benjamins, JS, Talamini, LM, Schalkwijk, F, Van Someren, EJW. Overnight worsening of emotional distress indicates maladaptive sleep in insomnia. Sleep. 2019; :. doi: 10.1093/sleep/zsz051. PubMed PMID:30907421 .
  13. Peraza, N, Torre, C, Álvarez, A, Villamor, P. Características otorrinolaringológicas en niños con trisomía 21: un estudio de 171 pacientes en el Hospital Infantil de México Federico Gómez. Bol Med Hosp Infant Mex. 2019;76 (2):87-94. doi: 10.24875/BMHIM.19000124. PubMed PMID:30907388 .
  14. Koffel, E, Amundson, E, Polusny, G, Wisdom, JP. "You're Missing Out on Something Great": Patient and Provider Perspectives on Increasing the Use of Cognitive Behavioral Therapy for Insomnia. Behav Sleep Med. 2019; :1-14. doi: 10.1080/15402002.2019.1591958. PubMed PMID:30907144 .
  15. Kim, H, Han, HJ. The Effect of Rivastigmine Transdermal Patch on Sleep Apnea in Patients with Probable Alzheimer's Disease. Dement Neurocogn Disord. 2016;15 (4):153-158. doi: 10.12779/dnd.2016.15.4.153. PubMed PMID:30906358 PubMed Central PMC6428022.
  16. Schennach, R, Feige, B, Riemann, D, Heuser, J, Voderholzer, U. Pre- to post-inpatient treatment of subjective sleep quality in 5,481 patients with mental disorders: A longitudinal analysis. J Sleep Res. 2019; :e12842. doi: 10.1111/jsr.12842. PubMed PMID:30907038 .
  17. Leong, P, Macdonald, MI, Ko, BS, Bardin, PG. Coexisting chronic obstructive pulmonary disease and cardiovascular disease in clinical practice: a diagnostic and therapeutic challenge. Med. J. Aust. 2019; :. doi: 10.5694/mja2.50120. PubMed PMID:30907000 .
  18. Ferini-Strambi, L, Galbiati, A, Combi, R. Sleep disorder-related headaches. Neurol. Sci. 2019; :. doi: 10.1007/s10072-019-03837-z. PubMed PMID:30906963 .
  19. Agrawal, VK, Kodur, S, Jha, RH. A Novel Grading System for Salpingopharyngeal Fold Hypertrophy in Obstructive Sleep Apnoea. Indian J Otolaryngol Head Neck Surg. 2019;71 (1):60-65. doi: 10.1007/s12070-018-1513-2. PubMed PMID:30906715 PubMed Central PMC6401366.
  20. Camacho, M, Certal, V, Modi, R, Capasso, R. Tissue-Sparing Uvulopalatopharyngoplasty for OSA: Conservative, Compassionate and Possibly just as Effective. Indian J Otolaryngol Head Neck Surg. 2019;71 (1):5-6. doi: 10.1007/s12070-015-0915-7. PubMed PMID:30906703 PubMed Central PMC6401053.
  21. Metersky, M, Chalmers, J. Bronchiectasis insanity: Doing the same thing over and over again and expecting different results?. F1000Res. 2019;8 :. doi: 10.12688/f1000research.17295.1. PubMed PMID:30906533 PubMed Central PMC6426099.
  22. Monneret, D. N-terminal pro-brain natriuretic peptide: a potential follow-up biomarker of mandibular advancement device efficacy on cardiac function in obstructive sleep apnea. F1000Res. 2018;7 :1818. doi: 10.12688/f1000research.17081.1. PubMed PMID:30906526 PubMed Central PMC6415324.
  23. Yanagisawa, M. Toward the Mysteries of Sleep. Keio J Med. 2019;68 (1):27. doi: 10.2302/kjm.68-001-ABST. PubMed PMID:30905886 .
  24. Eckert, L, Gupta, S, Gadkari, A, Mahajan, P, Gelfand, JM. Burden of illness in adults with atopic dermatitis (AD): analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain and the U.K. J. Am. Acad. Dermatol. 2019; :. doi: 10.1016/j.jaad.2019.03.037. PubMed PMID:30905805 .
  25. Lee, S, Buxton, OM, Andel, R, Almeida, DM. Bidirectional associations of sleep with cognitive interference in employees' work days. Sleep Health. 2019; :. doi: 10.1016/j.sleh.2019.01.007. PubMed PMID:30905693 .
Search PubMed

Search Terms: Insomnia, Narcolepsy, REM Sleep, Sleep Apnea, Sleep Quality